Melatech

Executive Summary

Melatech, founded in 2017 in San Francisco, is a biotechnology company pioneering the use of fungal melanin for advanced biomaterials. The company's core technology leverages melanin's unique properties—such as UV resistance, thermal stability, and electrical conductivity—to develop scalable solutions for radiation shielding, thermal management, and bioelectronics. These applications address critical challenges in both terrestrial industries and space exploration, positioning Melatech as a key player in the emerging bio-based materials sector. The company's strategic collaborations with NASA and the U.S. Department of Defense underscore its potential to serve high-stakes markets requiring robust, lightweight, and multifunctional materials. Melatech is advancing toward commercialization with a focus on near-term opportunities in aerospace and defense. Its fungal melanin production process is designed for scalability, which could enable cost-effective alternatives to traditional shielding and thermal materials. The company's engagement with government agencies not only validates its technology but also opens doors for phased contracts and grant funding. Beyond defense and space, Melatech's materials have potential in consumer electronics and medical devices, where biocompatibility and durability are valued. With a strong intellectual property foundation and growing interest in melanin-based solutions, Melatech is well-positioned to capture value in niche but expanding markets.

Upcoming Catalysts (preview)

• Q3 2026NASA Contract Award for Radiation Shielding70% success
• Q2 2026Commercial Launch of Thermal Management Product50% success
• Q4 2026Series B Funding Round60% success